Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 1,977 | 0.76 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3283
Sealed predictions
- CPT1A in dopamine neurons, braak-0.15 (p 0.705) → -0.24 (p 0.533)receipt 3290
Swarm cases
receipt 3290: CPT1A in dopamine neurons, braak
- power
- full sample -0.15 (p 0.544, n 18), 95% CI -0.58 to +0.34. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.413, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.434, n 18). could be the mix.
- skeptic
- leave-one-out range -0.30 to -0.04, sign flips 0; without severely affected donors -0.15 (p 0.544, n 18). fragile.
- cell type
- strongest in microglia: -0.63 (p 0.0049, n 18) vs -0.15 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CPT1A in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CPT1A · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.07 p 0.790 (needs p < 5.7e-4)
Receipts
loading the receipts